Hookipa Pharma Inc. Share Price (NASDAQ: HOOK)

$0.83

▲

-0.01

(-1.19%)

Last updated on August 7, 2025 at 12:00 AM IST

$₹

The stock has been delisted from the stock exchange on 7 Aug 2025

Check the interactive Hookipa Pharma Inc. Stock chart to analyse performance

Hookipa Pharma Inc. Key Stats

Check Hookipa Pharma Inc. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.84
Open	$0.885
Market Capitalization	$11.0M
Today's Volume	$125.4K
Revenue TTM	$9.4M
EBITDA	$-72.4M
Earnings Per Share (EPS)	$-5.44
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-105.79%

Global Institutional Holdings in Hookipa Pharma Inc.

Name
Holdings %
Name
Holdings %
Baker Bros Advisors LP
6.67%
Siren, L.L.C.
4.65%
FMR Inc
2.87%
Vanguard Group Inc
2.47%
Geode Capital Management, LLC
0.60%
Acadian Asset Management LLC
0.46%

Analyst Recommendation on Hookipa Pharma Inc. Stock

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Hookipa Pharma Inc.(by analysts ranked 0 to 5 stars)

Hookipa Pharma Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$11.9M	↑ 56.53%
Net Income	$-34.1M	↑ 110.3%
Net Profit Margin	-285.94%	↓ 73.11%

	FY20	Y/Y Change
Revenue	$19.6M	↑ 63.99%
Net Income	$-33.8M	↓ 1.01%
Net Profit Margin	-172.59%	↑ 113.35%

	FY21	Y/Y Change
Revenue	$18.4M	↓ 5.8%
Net Income	$-75.7M	↑ 123.86%
Net Profit Margin	-410.16%	↓ 237.57%

	FY22	Y/Y Change
Revenue	$14.2M	↓ 22.76%
Net Income	$-65.1M	↓ 13.9%
Net Profit Margin	-457.19%	↓ 47.03%

	FY23	Y/Y Change
Revenue	$20.1M	↑ 41.27%
Net Income	$-81.6M	↑ 25.23%
Net Profit Margin	-405.29%	↑ 51.9%

	FY24	Y/Y Change
Revenue	$43.9M	↑ 118.32%
Net Income	$-43.5M	↓ 46.67%
Net Profit Margin	-98.99%	↑ 306.3%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Revenue	$7.4M	↑ 7.86%
Net Income	$-24.8M	↑ 30.17%
Net Profit Margin	-335.06%	↓ 57.41%

	Q1 FY24	Q/Q Change
Revenue	$36.6M	↑ 394.11%
Net Income	$14.4M	↓ 157.95%
Net Profit Margin	39.3%	↑ 374.36%

	Q2 FY24	Q/Q Change
Revenue	$1.3M	↓ 96.48%
Net Income	$-19.1M	↓ 232.76%
Net Profit Margin	-1.5K%	↓ 1519.53%

	Q3 FY24	Q/Q Change
Revenue	$4.7M	↑ 264.57%
Net Income	$-13.8M	↓ 27.52%
Net Profit Margin	-294.3%	↑ 1185.93%

	Q4 FY24	Q/Q Change
Revenue	$1.4M	↓ 71.21%
Net Income	$-25.0M	↑ 80.26%
Net Profit Margin	-1.8K%	↓ 1548.39%

	Q1 FY25	Q/Q Change
Revenue	$2.0M	↑ 48.01%
Net Income	$-15.4M	↓ 38.17%
Net Profit Margin	-769.81%	↑ 1072.88%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$11.9M	↓ 183.3%

	FY20	Y/Y Change
Profit	$19.6M	↑ 63.99%

	FY21	Y/Y Change
Profit	$18.4M	↓ 5.8%

	FY22	Y/Y Change
Profit	$14.2M	↓ 22.76%

	FY23	Y/Y Change
Profit	$16.6M	↑ 16.34%

	FY24	Y/Y Change
Profit	$43.9M	↑ 165.1%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Profit	$6.1M	↓ 3.93%

	Q1 FY24	Q/Q Change
Profit	$36.6M	↑ 497.14%

	Q2 FY24	Q/Q Change
Profit	$1.3M	↓ 96.48%

	Q3 FY24	Q/Q Change
Profit	$4.7M	↑ 264.57%

	Q4 FY24	Q/Q Change
Profit	$1.4M	↓ 71.21%

	Q1 FY25	Q/Q Change
Profit	$2.0M	↑ 48.01%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-41.7M	↑ 178.24%
Investing Cash Flow	$-2.0M	↓ 7.02%
Financing Cash Flow	$109.8M	↑ 1496.84%

	FY20	Y/Y Change
Operating Cash Flow	$-39.3M	↓ 5.73%
Investing Cash Flow	$-2.4M	↑ 18.61%
Financing Cash Flow	$73.4M	↓ 33.1%

	FY21	Y/Y Change
Operating Cash Flow	$-66.0M	↑ 67.81%
Investing Cash Flow	$-12.6M	↑ 430.62%
Financing Cash Flow	$-235.0K	↓ 100.32%

	FY22	Y/Y Change
Operating Cash Flow	$-20.0M	↓ 69.71%
Investing Cash Flow	$-5.0M	↓ 60.12%
Financing Cash Flow	$72.3M	↓ 30853.62%

	FY23	Y/Y Change
Operating Cash Flow	$-57.5M	↑ 187.66%
Investing Cash Flow	$-4.2M	↓ 17.1%
Financing Cash Flow	$65.7M	↓ 9.13%

	FY24	Y/Y Change
Operating Cash Flow	$-77.0M	↑ 33.82%
Investing Cash Flow	$-194.0K	↓ 95.34%
Financing Cash Flow	$-1.3M	↓ 101.94%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Operating Cash Flow	$-11.2M	↓ 53.46%
Investing Cash Flow	$-422.0K	↓ 86.02%
Financing Cash Flow	$21.2M	↓ 3324.43%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-24.2M	↑ 115.22%
Investing Cash Flow	$-116.0K	↓ 72.51%
Financing Cash Flow	$-135.0K	↓ 100.64%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-14.4M	↓ 40.49%
Investing Cash Flow	$-45.0K	↓ 61.21%
Financing Cash Flow	$-1.1M	↑ 745.19%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-17.5M	↑ 21.79%
Investing Cash Flow	$-31.0K	↓ 31.11%
Financing Cash Flow	$0.0	↓ 100.0%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$52.0K	↓ 100.25%
Investing Cash Flow	$-20.0K	-
Financing Cash Flow	$0.0	-

About Hookipa Pharma Inc.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Organization	Hookipa Pharma Inc.
Employees	82
CEO	Dr. Malte Peters M.D.
Industry	Pharmaceuticals: Major

Key Management of Hookipa Pharma Inc.

Name	Title
Dr. Malte Peters M.D.	CEO, President & Director
Ms. Mary Theresa Coelho M.B.A.	Executive VP, CFO & Director
Dr. Daniel D. Pinschewer M.D.	Co-Founder & Member of Scientific Advisory Board
Dr. Mark Winderlich Ph.D.	Chief Research & Development Officer

Important FAQs about investing in HOOK Stock from India :

What is Hookipa Pharma Inc. share price today?

Hookipa Pharma Inc. share price today is $0.83 as on August 7, 2025 at 12:00 AM IST at the close of the market. Hookipa Pharma Inc. share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Hookipa Pharma Inc. share?

Hookipa Pharma Inc. share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Hookipa Pharma Inc. stock price today i.e. August 7, 2025 at 12:00 AM IST is closed at $0.83, lower by 85.34% versus the 52 week high.

How to invest in Hookipa Pharma Inc. Stock (HOOK) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Hookipa Pharma Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Hookipa Pharma Inc. Shares that will get you 1.8072 shares as per Hookipa Pharma Inc. share price of $0.83 per share as on August 7, 2025 at 12:00 AM IST.

What is the minimum amount required to buy Hookipa Pharma Inc. Stock (HOOK) from India?

Indian investors can start investing in Hookipa Pharma Inc. (HOOK) shares with as little as ₹87.2 or $1 (as of August 22, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹872.00 in Hookipa Pharma Inc. stock (as per the Rupee-Dollar exchange rate as on August 22, 2025). Based on Hookipa Pharma Inc. share’s latest price of $0.83 as on August 7, 2025 at 12:00 AM IST, you will get 12.0482 shares of Hookipa Pharma Inc.. Learn more about fractional shares .

What are the returns that Hookipa Pharma Inc. has given to Indian investors in the last 5 years?

Hookipa Pharma Inc. stock has given 0.0% share price returns and 17.57% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?

Discover More

Ishares Morningstar Value Etf
$86.20
-0.36%
Nexpoint Diversified Real Estate Trust
$3.87
+3.2%
Fair Isaac Corp
$1,363.09
+1.41%
Ab Tax-aware Short Duration Municipal Etf
$25.21
+0.0%
Graniteshares 2x Long Tsla Daily Etf
$18.30
-2.3%
Blackrock Muniholdings Ca Qu
$10.12
+0.1%
Alpha Capital Acquisition Co - Class A
$10.29
+0.19%
Netclass Technology
$1.82
+6.43%
Nuveen Global H-i Fd
$13.37
-0.37%

Explore all